Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

3.86
+0.01500.39%
Volume:307.66K
Turnover:1.19M
Market Cap:294.13M
PE:-3.18
High:3.89
Open:3.87
Low:3.84
Close:3.84
52wk High:15.74
52wk Low:2.83
Shares:76.30M
Float Shares:63.49M
Volume Ratio:0.33
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2104
EPS(LYR):-1.1819
ROE:-32.38%
ROA:-19.59%
PB:0.95
PE(LYR):-3.26

Loading ...

Fulcrum Therapeutics Inc - Plans to Initiate Registration-Enabling Trial for Pociredir in H2 2026

THOMSON REUTERS
·
Apr 27

Fulcrum Therapeutics Inc - Ends Q1 2026 With $333.3 Mln in Cash and Securities; Cash Runway Into 2029

THOMSON REUTERS
·
Apr 27

Fulcrum Therapeutics Q1 Operating Expenses USD 22.186 Million

THOMSON REUTERS
·
Apr 27

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

GlobeNewswire
·
Apr 27

Fulcrum Therapeutics names Marea CEO Josh Lehrer to board as independent director

Reuters
·
Apr 27

Fulcrum Therapeutics Appoints Josh Lehrer to Its Board of Directors

THOMSON REUTERS
·
Apr 27

Press Release: Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Dow Jones
·
Apr 27

U.S. Earnings Preview: Before Market Open April 27

Dow Jones
·
Apr 27

Top News Today/Canada: Retail Sales Improve Ahead of Expected Squeeze

Dow Jones
·
Apr 25

Fulcrum Therapeutics schedules first-quarter financial results call and webcast

Reuters
·
Apr 20

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
Apr 01

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

GlobeNewswire
·
Mar 19

Fulcrum Therapeutics grants 34,000 inducement stock options to new employee

Reuters
·
Mar 07

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Fulcrum Therapeutics Charts Pivotal Path After Earnings Call

TIPRANKS
·
Mar 02

Fulcrum Therapeutics price target lowered to $17 from $18 at Truist

TIPRANKS
·
Feb 25